Financials

This section of the Anika Therapeutics, Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.

Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. COMPANY NAME assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQANIK

Beta	0.86
Shares Outstanding	14.6M
Average Volume (10 days)	110.7K
Qtrly Dividend (Ann. Yield)	-- (--)

Per Share Data

Earnings (TTM)	($1.03)
Sales (TTM)	$10.68
Book Value (MRQ)	$19.52
Cash Flow (TTM)	$0.30
Cash (MRQ)	$5.90

Analyst Views

Current Mean Recommendation	Hold

Strong Buy	0
Buy	0
Hold	2
Underperform	0
Sell	0

Recent Insider Transactions

Michael L. Levitz EVP, CFO, Treasurer	(2,609) Dispose Mar 10, 2023
David Colleran EVP, General Counsel, Corp Sec	(2,250) Dispose Mar 10, 2023
Cheryl R. Blanchard Director, President, CEO, Director	(13,211) Dispose Mar 10, 2023
Michael L. Levitz EVP, CFO, Treasurer	(1,303) Dispose Mar 9, 2023
David Colleran EVP, General Counsel, Corp Sec	(1,081) Dispose Mar 9, 2023

Recent SEC Filings

10-K 10-K	Mar 16, 2023
4 Insider Buy/Sell	Mar 14, 2023
4 Insider Buy/Sell	Mar 14, 2023
4 Insider Buy/Sell	Mar 14, 2023
4 Insider Buy/Sell	Mar 10, 2023

Currency in USD.
Quote data delayed by at least 15 minutes.
Earnings and Analyst data provided by Zacks.
Insiders data provided by Morningstar.